UNLOCKING THE POTENTIAL OF THE
IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Immunophotonics uses a proprietary glycan polymer with
platform potential to stimulate antigen capture and uptake along
with other immunological processes that are intended to trigger an
immune response, thereby enabling the rejection of cancer and other diseases.
Read More

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses.
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases.

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

News Highlights

June 1, 2023

Immunophotonics Announces 1st Patient Dosed in Multinational Clinical Trial in the United Kingdom

Latest News, Press Releases
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the...
Read More
May 18, 2023

Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S.

Latest News, Press Releases
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of...
Read More
January 26, 2023

Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications

Latest News, Press Releases
Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety...
Read More
1 2 3 4 5